19.05
+3.03%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Orient Gene Biotech Co
Its shares trade on Shanghai under the ticker 688298.SS. It has been listed since 5 February 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥959.0m and a net loss of CN¥563.6m. At that date it held total assets of CN¥7.14bn and shareholders' equity of CN¥5.99bn.
Zhejiang Orient Gene Biotech Co., Ltd. engages in the research, development, production and sales of in vitro diagnostic products. The company is headquartered in Huzhou, Zhejiang. The company went IPO on 2020-02-05. The firm's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The firm also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The firm operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 5 Feb 2020
- Employees
- 2,830
- Website
- orientgene.com ↗
Leadership
Pay as last reported
- Mr. Jianqiu FangChairman of the Board, since 2017CN¥1.1m
- Mr. Jinhong YuFinance Director, Deputy General ManagerCN¥1.1m
- Mr. Xiaoliang FangGeneral Manager, Director, since 2017CN¥1.2m
- Ms. Yeping ZhangDeputy General Manager, Secretary of the BoardCN¥918,900
- Mr. Yun OuyangDeputy General Manager
- Ms. Qi PangDeputy General ManagerCN¥841,700
- Ms. Jinfeng TanDeputy General ManagerCN¥853,600
- Ms. Faying XuDeputy General ManagerCN¥1.3m
- Ms. Yuzi ZhengDeputy General Manager
- Ms. Chunmei ZhongDeputy General ManagerCN¥845,300
- Mr. Xincheng FangDirector
- Mr. Luyi YanDirectorCN¥20,800
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Orient Gene Biotech employs 2830 full-time employees for robust R&D and production.
- The company's POCT instant diagnostic reagents are used in drug testing and infectious disease testing.
- Zhejiang Orient Gene Biotech operates in Mainland China, America, Europe, Asia, Africa, and Oceania.
Weaknesses
- The company's IPO was on 5 February 2020, which may indicate limited market history.
- Zhejiang Orient Gene Biotech's main products focus on diagnostic reagents without diversification.
- The firm's operations are primarily in the Health Care sector without expansion into other industries.
Opportunities
- Growing demand for POCT in drug testing and infectious disease testing across global markets.
- Expansion into new regions like Africa and Oceania for increased market share.
- Increasing use of biochemical diagnostic reagents in dry and fluid diagnostics globally.
Threats
- Competition in the Health Care sector from established biotechnology firms.
- Regulatory challenges in international markets for diagnostic products.
- Economic downturns affecting healthcare spending in global regions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.